AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
paliperidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antipsychotics, risperidone derivatives | 4137 | 144598-75-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 6 | mg | O |
| 2.50 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.03 mg/mL | Bocci G, Oprea TI, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 59 % | Benet LZ, Broccatelli F, Oprea TI |
| BA (Bioavailability) | 28 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| CL (Clearance) | 1.18 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.24 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 24.60 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | EIF2AK3,GRK2,PDK1,PDK2,PDK4 | 5 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 4.656 | Moderate | 0.76 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 | |
| rat-kpuu-brain | Rat brain Kpuu | 0.062 | % | Moderate | 0.76 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 25, 2007 | EMA | ||
| Dec. 19, 2006 | FDA | JANSSEN PHARMS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blood prolactin abnormal | 1265.10 | 25.33 | 246 | 14579 | 3020 | 90610602 |
| Dystonia | 1246.50 | 25.33 | 328 | 14497 | 16491 | 90597131 |
| Anosognosia | 1155.95 | 25.33 | 231 | 14594 | 3291 | 90610331 |
| Sexual dysfunction | 1101.57 | 25.33 | 234 | 14591 | 4570 | 90609052 |
| Disturbance in social behaviour | 1092.74 | 25.33 | 227 | 14598 | 3961 | 90609661 |
| Dyskinesia | 1060.04 | 25.33 | 344 | 14481 | 36190 | 90577432 |
| Galactorrhoea | 1056.59 | 25.33 | 225 | 14600 | 4447 | 90609175 |
| Metabolic disorder | 977.65 | 25.33 | 230 | 14595 | 7240 | 90606382 |
| Personality change | 919.31 | 25.33 | 218 | 14607 | 7103 | 90606519 |
| Sedation | 865.31 | 25.33 | 317 | 14508 | 47854 | 90565768 |
| Suicide attempt | 773.70 | 25.33 | 331 | 14494 | 75068 | 90538554 |
| Blood prolactin increased | 742.18 | 25.33 | 161 | 14664 | 3476 | 90610146 |
| Blood glucose increased | 486.59 | 25.33 | 259 | 14566 | 94987 | 90518635 |
| Hyperprolactinaemia | 465.11 | 25.33 | 119 | 14706 | 5314 | 90608308 |
| Extrapyramidal disorder | 437.75 | 25.33 | 145 | 14680 | 16158 | 90597464 |
| Amenorrhoea | 412.19 | 25.33 | 128 | 14697 | 11594 | 90602028 |
| Tardive dyskinesia | 341.20 | 25.33 | 109 | 14716 | 10821 | 90602801 |
| Psychotic disorder | 261.18 | 25.33 | 119 | 14706 | 31111 | 90582511 |
| Parkinsonism | 249.92 | 25.33 | 92 | 14733 | 13973 | 90599649 |
| Akathisia | 205.68 | 25.33 | 75 | 14750 | 11084 | 90602538 |
| Treatment noncompliance | 196.55 | 25.33 | 116 | 14709 | 51611 | 90562011 |
| Neuroleptic malignant syndrome | 187.09 | 25.33 | 76 | 14749 | 15020 | 90598602 |
| Schizophrenia | 181.12 | 25.33 | 74 | 14751 | 14840 | 90598782 |
| Hallucination, auditory | 176.20 | 25.33 | 74 | 14751 | 15901 | 90597721 |
| Intentional self-injury | 175.95 | 25.33 | 89 | 14736 | 29245 | 90584377 |
| Drug ineffective | 160.92 | 25.33 | 542 | 14283 | 1383756 | 89229866 |
| Delusion | 158.99 | 25.33 | 66 | 14759 | 13774 | 90599848 |
| Catatonia | 151.08 | 25.33 | 51 | 14774 | 6005 | 90607617 |
| Breast discharge | 144.99 | 25.33 | 35 | 14790 | 1224 | 90612398 |
| Intentional overdose | 144.56 | 25.33 | 121 | 14704 | 93713 | 90519909 |
| Insurance issue | 142.08 | 25.33 | 57 | 14768 | 10901 | 90602721 |
| Personality change due to a general medical condition | 107.01 | 25.33 | 21 | 14804 | 269 | 90613353 |
| Apraxia | 106.68 | 25.33 | 31 | 14794 | 2231 | 90611391 |
| Tremor | 101.29 | 25.33 | 125 | 14700 | 153048 | 90460574 |
| Adverse drug reaction | 100.26 | 25.33 | 109 | 14716 | 116592 | 90497030 |
| Head titubation | 95.03 | 25.33 | 25 | 14800 | 1243 | 90612379 |
| Hospitalisation | 93.62 | 25.33 | 110 | 14715 | 127990 | 90485632 |
| Mania | 90.99 | 25.33 | 45 | 14780 | 14079 | 90599543 |
| Diarrhoea | 83.80 | 25.33 | 25 | 14800 | 939165 | 89674457 |
| Polydipsia | 83.80 | 25.33 | 30 | 14795 | 4201 | 90609421 |
| Pain | 81.13 | 25.33 | 31 | 14794 | 996310 | 89617312 |
| Agitation | 80.25 | 25.33 | 75 | 14750 | 67023 | 90546599 |
| Completed suicide | 76.61 | 25.33 | 106 | 14719 | 144952 | 90468670 |
| Schizoaffective disorder | 74.51 | 25.33 | 29 | 14796 | 5118 | 90608504 |
| Aggression | 73.95 | 25.33 | 49 | 14776 | 26619 | 90587003 |
| Arthralgia | 72.60 | 25.33 | 19 | 14806 | 778503 | 89835119 |
| Myocarditis | 71.57 | 25.33 | 38 | 14787 | 13768 | 90599854 |
| Salivary hypersecretion | 70.81 | 25.33 | 33 | 14792 | 9059 | 90604563 |
| Oculogyric crisis | 66.28 | 25.33 | 22 | 14803 | 2457 | 90611165 |
| Movement disorder | 63.28 | 25.33 | 46 | 14779 | 28973 | 90584649 |
| Condition aggravated | 60.47 | 25.33 | 224 | 14601 | 595321 | 90018301 |
| Weight increased | 58.24 | 25.33 | 175 | 14650 | 417752 | 90195870 |
| Paranoia | 57.13 | 25.33 | 32 | 14793 | 12876 | 90600746 |
| Myoclonus | 55.04 | 25.33 | 36 | 14789 | 19132 | 90594490 |
| Abnormal behaviour | 54.24 | 25.33 | 38 | 14787 | 22590 | 90591032 |
| Somnolence | 54.08 | 25.33 | 111 | 14714 | 208973 | 90404649 |
| Tachycardia | 53.51 | 25.33 | 94 | 14731 | 157579 | 90456043 |
| Overdose | 53.50 | 25.33 | 94 | 14731 | 157615 | 90456007 |
| Nausea | 52.40 | 25.33 | 63 | 14762 | 1110253 | 89503369 |
| Alopecia | 52.39 | 25.33 | 9 | 14816 | 495062 | 90118560 |
| Psychotic symptom | 52.35 | 25.33 | 18 | 14807 | 2238 | 90611384 |
| Metabolic syndrome | 51.51 | 25.33 | 17 | 14808 | 1865 | 90611757 |
| Drug hypersensitivity | 50 | 25.33 | 8 | 14817 | 463601 | 90150021 |
| Joint swelling | 49.36 | 25.33 | 11 | 14814 | 503289 | 90110333 |
| Breast enlargement | 48.63 | 25.33 | 16 | 14809 | 1739 | 90611883 |
| Sinus tachycardia | 48.53 | 25.33 | 39 | 14786 | 28474 | 90585148 |
| Depressive symptom | 46.87 | 25.33 | 21 | 14804 | 5264 | 90608358 |
| Drug interaction | 46.51 | 25.33 | 124 | 14701 | 276329 | 90337293 |
| Suicidal ideation | 45.14 | 25.33 | 58 | 14767 | 73797 | 90539825 |
| Sinusitis | 44.43 | 25.33 | 3 | 14822 | 343085 | 90270537 |
| Pain in extremity | 43.86 | 25.33 | 10 | 14815 | 450519 | 90163103 |
| Headache | 42.75 | 25.33 | 47 | 14778 | 862699 | 89750923 |
| Rash | 42.11 | 25.33 | 41 | 14784 | 796059 | 89817563 |
| Infection | 41.97 | 25.33 | 5 | 14820 | 362089 | 90251533 |
| Muscle rigidity | 41.39 | 25.33 | 27 | 14798 | 14282 | 90599340 |
| Psychiatric decompensation | 39.32 | 25.33 | 14 | 14811 | 1929 | 90611693 |
| Rhabdomyolysis | 39.04 | 25.33 | 45 | 14780 | 51211 | 90562411 |
| Fatigue | 38.79 | 25.33 | 82 | 14743 | 1153941 | 89459681 |
| Abdominal discomfort | 38.47 | 25.33 | 15 | 14810 | 477313 | 90136309 |
| Nasopharyngitis | 37.74 | 25.33 | 10 | 14815 | 407094 | 90206528 |
| Personality disorder | 37.27 | 25.33 | 24 | 14801 | 12420 | 90601202 |
| Blood creatine phosphokinase increased | 36.81 | 25.33 | 36 | 14789 | 33987 | 90579635 |
| Wound | 35.56 | 25.33 | 4 | 14821 | 302976 | 90310646 |
| Psychiatric symptom | 35.23 | 25.33 | 19 | 14806 | 7099 | 90606523 |
| Psychotic behaviour | 35.16 | 25.33 | 10 | 14815 | 666 | 90612956 |
| Peripheral swelling | 34.94 | 25.33 | 12 | 14813 | 413094 | 90200528 |
| Pneumonia | 34.72 | 25.33 | 32 | 14793 | 638027 | 89975595 |
| Hypersensitivity | 33.91 | 25.33 | 16 | 14809 | 454661 | 90158961 |
| Discomfort | 33.82 | 25.33 | 3 | 14822 | 274332 | 90339290 |
| Altered state of consciousness | 33.43 | 25.33 | 33 | 14792 | 31499 | 90582123 |
| Pruritus | 33.38 | 25.33 | 24 | 14801 | 541501 | 90072121 |
| Anger | 32.78 | 25.33 | 23 | 14802 | 13697 | 90599925 |
| Monocyte count decreased | 31.93 | 25.33 | 13 | 14812 | 2578 | 90611044 |
| Psychomotor hyperactivity | 31.83 | 25.33 | 22 | 14803 | 12791 | 90600831 |
| Abdominal pain upper | 31.15 | 25.33 | 8 | 14817 | 332666 | 90280956 |
| Electrocardiogram QT prolonged | 31.03 | 25.33 | 48 | 14777 | 72408 | 90541214 |
| Mental impairment | 30.88 | 25.33 | 24 | 14801 | 16696 | 90596926 |
| Ovarian germ cell cancer stage II | 30.86 | 25.33 | 6 | 14819 | 73 | 90613549 |
| Drooling | 30.81 | 25.33 | 15 | 14810 | 4531 | 90609091 |
| Lactate pyruvate ratio increased | 30.42 | 25.33 | 6 | 14819 | 79 | 90613543 |
| Mobility decreased | 30.22 | 25.33 | 3 | 14822 | 250731 | 90362891 |
| Lower respiratory tract infection | 30.21 | 25.33 | 3 | 14822 | 250656 | 90362966 |
| Restlessness | 30.00 | 25.33 | 33 | 14792 | 35687 | 90577935 |
| Regressive behaviour | 30.00 | 25.33 | 7 | 14818 | 211 | 90613411 |
| Hepatic enzyme increased | 29.61 | 25.33 | 11 | 14814 | 360725 | 90252897 |
| Swelling | 29.36 | 25.33 | 16 | 14809 | 419042 | 90194580 |
| Trichoglossia | 29.36 | 25.33 | 8 | 14817 | 455 | 90613167 |
| Diabetes insipidus | 29.24 | 25.33 | 13 | 14812 | 3199 | 90610423 |
| Decreased appetite | 28.45 | 25.33 | 13 | 14812 | 376527 | 90237095 |
| Sopor | 28.40 | 25.33 | 27 | 14798 | 24617 | 90589005 |
| Wheezing | 28.30 | 25.33 | 3 | 14822 | 238077 | 90375545 |
| Contusion | 27.82 | 25.33 | 4 | 14821 | 251212 | 90362410 |
| Dyspnoea | 27.57 | 25.33 | 65 | 14760 | 880890 | 89732732 |
| General physical health deterioration | 27.24 | 25.33 | 12 | 14813 | 355103 | 90258519 |
| Gender dysphoria | 26.48 | 25.33 | 4 | 14821 | 8 | 90613614 |
| Blood citric acid increased | 26.35 | 25.33 | 5 | 14820 | 53 | 90613569 |
| Epileptic encephalopathy | 25.97 | 25.33 | 7 | 14818 | 382 | 90613240 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Gynaecomastia | 773.15 | 23.97 | 257 | 15996 | 12310 | 42592772 |
| Dystonia | 515.48 | 23.97 | 191 | 16062 | 12599 | 42592483 |
| Treatment noncompliance | 446.08 | 23.97 | 238 | 16015 | 37434 | 42567648 |
| Akathisia | 420.79 | 23.97 | 156 | 16097 | 10295 | 42594787 |
| Extrapyramidal disorder | 391.79 | 23.97 | 168 | 16085 | 16244 | 42588838 |
| Psychotic disorder | 369.66 | 23.97 | 193 | 16060 | 29015 | 42576067 |
| Sedation | 331.23 | 23.97 | 182 | 16071 | 30293 | 42574789 |
| Weight increased | 297.75 | 23.97 | 279 | 15974 | 107704 | 42497378 |
| Neuroleptic malignant syndrome | 295.00 | 23.97 | 150 | 16103 | 21322 | 42583760 |
| Anosognosia | 241.43 | 23.97 | 60 | 16193 | 984 | 42604098 |
| Intentional self-injury | 240.74 | 23.97 | 117 | 16136 | 15085 | 42589997 |
| Hyperprolactinaemia | 229.81 | 23.97 | 67 | 16186 | 2056 | 42603026 |
| Sexual dysfunction | 221.76 | 23.97 | 87 | 16166 | 6688 | 42598394 |
| Emotional disorder | 216.99 | 23.97 | 84 | 16169 | 6230 | 42598852 |
| Blood prolactin abnormal | 206.17 | 23.97 | 53 | 16200 | 1002 | 42604080 |
| Disturbance in social behaviour | 191.18 | 23.97 | 56 | 16197 | 1747 | 42603335 |
| Delusion | 188.05 | 23.97 | 98 | 16155 | 14636 | 42590446 |
| Suicide attempt | 185.42 | 23.97 | 148 | 16105 | 45952 | 42559130 |
| Dyskinesia | 184.59 | 23.97 | 117 | 16136 | 25273 | 42579809 |
| Hallucination, auditory | 178.72 | 23.97 | 95 | 16158 | 14769 | 42590313 |
| Schizophrenia | 166.40 | 23.97 | 81 | 16172 | 10469 | 42594613 |
| Blood prolactin increased | 165.38 | 23.97 | 53 | 16200 | 2245 | 42602837 |
| Myocarditis | 141.96 | 23.97 | 89 | 16164 | 18849 | 42586233 |
| Metabolic disorder | 134.20 | 23.97 | 55 | 16198 | 4733 | 42600349 |
| Tachycardia | 133.47 | 23.97 | 178 | 16075 | 100909 | 42504173 |
| Aggression | 125.00 | 23.97 | 116 | 16137 | 44047 | 42561035 |
| Mental impairment | 123.94 | 23.97 | 70 | 16183 | 12247 | 42592835 |
| Drug ineffective | 123.36 | 23.97 | 519 | 15734 | 629678 | 41975404 |
| Intentional overdose | 122.72 | 23.97 | 123 | 16130 | 51333 | 42553749 |
| Sedation complication | 118.96 | 23.97 | 44 | 16209 | 2875 | 42602207 |
| Salivary hypersecretion | 117.76 | 23.97 | 65 | 16188 | 10878 | 42594204 |
| Loss of libido | 116.80 | 23.97 | 44 | 16209 | 3026 | 42602056 |
| Obesity | 115.00 | 23.97 | 74 | 16179 | 16385 | 42588697 |
| Apathy | 110.35 | 23.97 | 57 | 16196 | 8349 | 42596733 |
| Tardive dyskinesia | 105.69 | 23.97 | 52 | 16201 | 6872 | 42598210 |
| Galactorrhoea | 101.75 | 23.97 | 26 | 16227 | 479 | 42604603 |
| Psychotic symptom | 100.99 | 23.97 | 37 | 16216 | 2353 | 42602729 |
| Suicidal ideation | 93.19 | 23.97 | 103 | 16150 | 48058 | 42557024 |
| Hospitalisation | 92.11 | 23.97 | 127 | 16126 | 74203 | 42530879 |
| Parkinsonism | 89.99 | 23.97 | 54 | 16199 | 10569 | 42594513 |
| Diarrhoea | 88.18 | 23.97 | 33 | 16220 | 460816 | 42144266 |
| Catatonia | 86.80 | 23.97 | 44 | 16209 | 6195 | 42598887 |
| Abnormal weight gain | 85.26 | 23.97 | 28 | 16225 | 1282 | 42603800 |
| Mania | 82.63 | 23.97 | 51 | 16202 | 10496 | 42594586 |
| Tremor | 81.07 | 23.97 | 138 | 16115 | 96791 | 42508291 |
| Persecutory delusion | 80.09 | 23.97 | 35 | 16218 | 3529 | 42601553 |
| Hallucination | 80.02 | 23.97 | 104 | 16149 | 57403 | 42547679 |
| Agitation | 79.84 | 23.97 | 110 | 16143 | 64204 | 42540878 |
| Personality change | 75.69 | 23.97 | 39 | 16214 | 5680 | 42599402 |
| Abnormal behaviour | 73.87 | 23.97 | 69 | 16184 | 26382 | 42578700 |
| Drooling | 73.81 | 23.97 | 35 | 16218 | 4264 | 42600818 |
| Paranoia | 71.69 | 23.97 | 52 | 16201 | 13974 | 42591108 |
| Anaemia | 64.69 | 23.97 | 14 | 16239 | 280264 | 42324818 |
| Emotional distress | 63.19 | 23.97 | 51 | 16202 | 16042 | 42589040 |
| Psychiatric symptom | 56.35 | 23.97 | 29 | 16224 | 4212 | 42600870 |
| Priapism | 55.38 | 23.97 | 33 | 16220 | 6374 | 42598708 |
| Overweight | 55.22 | 23.97 | 24 | 16229 | 2388 | 42602694 |
| Arthralgia | 54.52 | 23.97 | 7 | 16246 | 205231 | 42399851 |
| Muscle rigidity | 53.34 | 23.97 | 41 | 16212 | 12018 | 42593064 |
| Blood creatine phosphokinase increased | 53.06 | 23.97 | 78 | 16175 | 48260 | 42556822 |
| Febrile neutropenia | 52.70 | 23.97 | 5 | 16248 | 185698 | 42419384 |
| Sepsis | 52.47 | 23.97 | 7 | 16246 | 199327 | 42405755 |
| Blepharospasm | 49.84 | 23.97 | 19 | 16234 | 1349 | 42603733 |
| Jaw clicking | 49.43 | 23.97 | 10 | 16243 | 59 | 42605023 |
| Pleurothotonus | 48.41 | 23.97 | 18 | 16235 | 1193 | 42603889 |
| Rhabdomyolysis | 46.35 | 23.97 | 96 | 16157 | 77923 | 42527159 |
| Death | 45.99 | 23.97 | 68 | 16185 | 471117 | 42133965 |
| Somnolence | 45.06 | 23.97 | 137 | 16116 | 140968 | 42464114 |
| Thrombocytopenia | 44.90 | 23.97 | 9 | 16244 | 190270 | 42414812 |
| Pneumonia | 44.10 | 23.97 | 58 | 16195 | 422091 | 42182991 |
| Sinus tachycardia | 43.10 | 23.97 | 46 | 16207 | 20607 | 42584475 |
| Blood osmolarity decreased | 42.75 | 23.97 | 14 | 16239 | 635 | 42604447 |
| Thinking abnormal | 42.27 | 23.97 | 29 | 16224 | 7132 | 42597950 |
| Anion gap increased | 42.03 | 23.97 | 19 | 16234 | 2075 | 42603007 |
| Acute kidney injury | 40.93 | 23.97 | 48 | 16205 | 367289 | 42237793 |
| Blood glucose increased | 40.66 | 23.97 | 88 | 16165 | 73611 | 42531471 |
| Conversion disorder | 40.63 | 23.97 | 13 | 16240 | 547 | 42604535 |
| Pruritus | 40.44 | 23.97 | 11 | 16242 | 188760 | 42416322 |
| Disease progression | 40.39 | 23.97 | 4 | 16249 | 143652 | 42461430 |
| Hypometabolism | 39.94 | 23.97 | 10 | 16243 | 169 | 42604913 |
| Sopor | 39.88 | 23.97 | 36 | 16217 | 13166 | 42591916 |
| Social avoidant behaviour | 39 | 23.97 | 21 | 16232 | 3343 | 42601739 |
| Sluggishness | 38.79 | 23.97 | 22 | 16231 | 3874 | 42601208 |
| Antipsychotic drug level increased | 37.66 | 23.97 | 23 | 16230 | 4643 | 42600439 |
| Painful erection | 37.64 | 23.97 | 11 | 16242 | 340 | 42604742 |
| Cough | 35.21 | 23.97 | 12 | 16241 | 178091 | 42426991 |
| Restlessness | 34.72 | 23.97 | 49 | 16204 | 29200 | 42575882 |
| Nephrogenic diabetes insipidus | 33.88 | 23.97 | 15 | 16238 | 1559 | 42603523 |
| Intentional product misuse | 31.97 | 23.97 | 72 | 16181 | 61828 | 42543254 |
| Nausea | 31.62 | 23.97 | 65 | 16188 | 396734 | 42208348 |
| Myelocyte count increased | 31.53 | 23.97 | 10 | 16243 | 409 | 42604673 |
| Water intoxication | 31.51 | 23.97 | 10 | 16243 | 410 | 42604672 |
| Drug use disorder | 30.86 | 23.97 | 28 | 16225 | 10305 | 42594777 |
| Dyspnoea | 30.83 | 23.97 | 78 | 16175 | 442543 | 42162539 |
| Drug interaction | 29.96 | 23.97 | 189 | 16064 | 266810 | 42338272 |
| Paradoxical drug reaction | 29.90 | 23.97 | 20 | 16233 | 4718 | 42600364 |
| Inappropriate affect | 29.35 | 23.97 | 11 | 16242 | 745 | 42604337 |
| Bruxism | 29.30 | 23.97 | 15 | 16238 | 2154 | 42602928 |
| Troponin I increased | 29.28 | 23.97 | 17 | 16236 | 3129 | 42601953 |
| Yawning | 28.99 | 23.97 | 11 | 16242 | 771 | 42604311 |
| Housebound | 27.89 | 23.97 | 8 | 16245 | 231 | 42604851 |
| Pancytopenia | 26.87 | 23.97 | 6 | 16247 | 117737 | 42487345 |
| Eye movement disorder | 26.79 | 23.97 | 19 | 16234 | 4926 | 42600156 |
| Gastrointestinal haemorrhage | 26.74 | 23.97 | 3 | 16250 | 97723 | 42507359 |
| Olfactory nerve disorder | 26.52 | 23.97 | 6 | 16247 | 64 | 42605018 |
| Completed suicide | 26.50 | 23.97 | 89 | 16164 | 96376 | 42508706 |
| Metamyelocyte count increased | 26.47 | 23.97 | 9 | 16244 | 459 | 42604623 |
| Increased appetite | 26.34 | 23.97 | 24 | 16229 | 8882 | 42596200 |
| Renal failure | 26.20 | 23.97 | 11 | 16242 | 143715 | 42461367 |
| Illusion | 26.06 | 23.97 | 11 | 16242 | 1018 | 42604064 |
| Trismus | 25.30 | 23.97 | 15 | 16238 | 2869 | 42602213 |
| Delusional perception | 25.18 | 23.97 | 7 | 16246 | 180 | 42604902 |
| Blood bicarbonate decreased | 25.06 | 23.97 | 15 | 16238 | 2920 | 42602162 |
| Infection | 25.00 | 23.97 | 6 | 16247 | 112062 | 42493020 |
| Arrhythmia | 24.38 | 23.97 | 50 | 16203 | 40267 | 42564815 |
| Troponin increased | 24.22 | 23.97 | 33 | 16220 | 19029 | 42586053 |
| Inappropriate schedule of product administration | 24.19 | 23.97 | 86 | 16167 | 95816 | 42509266 |
| Protein total increased | 24.17 | 23.97 | 14 | 16239 | 2564 | 42602518 |
| Pain | 24.13 | 23.97 | 35 | 16218 | 244813 | 42360269 |
| Drug level below therapeutic | 24.13 | 23.97 | 20 | 16233 | 6525 | 42598557 |
| Pyrexia | 24.03 | 23.97 | 74 | 16179 | 393968 | 42211114 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dystonia | 1389.47 | 23.35 | 418 | 23837 | 25387 | 110539657 |
| Blood prolactin abnormal | 1198.60 | 23.35 | 254 | 24001 | 3581 | 110561463 |
| Anosognosia | 1188.96 | 23.35 | 255 | 24000 | 3819 | 110561225 |
| Sexual dysfunction | 1100.77 | 23.35 | 275 | 23980 | 8255 | 110556789 |
| Disturbance in social behaviour | 1063.52 | 23.35 | 242 | 24013 | 4816 | 110560228 |
| Dyskinesia | 988.20 | 23.35 | 385 | 23870 | 51061 | 110513983 |
| Sedation | 943.97 | 23.35 | 406 | 23849 | 69277 | 110495767 |
| Metabolic disorder | 920.46 | 23.35 | 249 | 24006 | 10261 | 110554783 |
| Personality change | 839.94 | 23.35 | 234 | 24021 | 10768 | 110554276 |
| Suicide attempt | 788.14 | 23.35 | 405 | 23850 | 102989 | 110462055 |
| Galactorrhoea | 627.13 | 23.35 | 152 | 24103 | 4003 | 110561041 |
| Extrapyramidal disorder | 585.71 | 23.35 | 225 | 24030 | 28642 | 110536402 |
| Gynaecomastia | 576.73 | 23.35 | 169 | 24086 | 9321 | 110555723 |
| Akathisia | 517.18 | 23.35 | 179 | 24076 | 16934 | 110548110 |
| Blood prolactin increased | 468.02 | 23.35 | 123 | 24132 | 4519 | 110560525 |
| Hyperprolactinaemia | 466.00 | 23.35 | 132 | 24123 | 6443 | 110558601 |
| Neuroleptic malignant syndrome | 462.43 | 23.35 | 199 | 24056 | 33860 | 110531184 |
| Treatment noncompliance | 448.72 | 23.35 | 248 | 24007 | 72742 | 110492302 |
| Intentional self-injury | 438.00 | 23.35 | 197 | 24058 | 37232 | 110527812 |
| Blood glucose increased | 403.01 | 23.35 | 288 | 23967 | 132208 | 110432836 |
| Psychotic disorder | 391.79 | 23.35 | 201 | 24054 | 50736 | 110514308 |
| Parkinsonism | 302.27 | 23.35 | 130 | 24125 | 22057 | 110542987 |
| Delusion | 274.54 | 23.35 | 124 | 24131 | 23631 | 110541413 |
| Tardive dyskinesia | 272.27 | 23.35 | 105 | 24150 | 13474 | 110551570 |
| Hallucination, auditory | 268.20 | 23.35 | 126 | 24129 | 26271 | 110538773 |
| Schizophrenia | 255.63 | 23.35 | 115 | 24140 | 21711 | 110543333 |
| Drug ineffective | 252.54 | 23.35 | 816 | 23439 | 1519724 | 109045320 |
| Intentional overdose | 243.04 | 23.35 | 214 | 24041 | 132287 | 110432757 |
| Myocarditis | 226.38 | 23.35 | 117 | 24138 | 29938 | 110535106 |
| Amenorrhoea | 212.61 | 23.35 | 79 | 24176 | 9152 | 110555892 |
| Salivary hypersecretion | 207.85 | 23.35 | 93 | 24162 | 17328 | 110547716 |
| Catatonia | 197.09 | 23.35 | 79 | 24176 | 11221 | 110553823 |
| Tachycardia | 169.65 | 23.35 | 228 | 24027 | 226417 | 110338627 |
| Weight increased | 149.80 | 23.35 | 302 | 23953 | 419342 | 110145702 |
| Insurance issue | 140.63 | 23.35 | 61 | 24194 | 10551 | 110554493 |
| Diarrhoea | 135.72 | 23.35 | 41 | 24214 | 1139464 | 109425580 |
| Psychotic symptom | 134.60 | 23.35 | 45 | 24210 | 3822 | 110561222 |
| Mental impairment | 130.98 | 23.35 | 74 | 24181 | 22565 | 110542479 |
| Tremor | 125.41 | 23.35 | 186 | 24069 | 202046 | 110362998 |
| Agitation | 120.53 | 23.35 | 136 | 24119 | 112915 | 110452129 |
| Aggression | 119.32 | 23.35 | 101 | 24154 | 59109 | 110505935 |
| Adverse drug reaction | 117.70 | 23.35 | 130 | 24125 | 105429 | 110459615 |
| Mania | 117.68 | 23.35 | 67 | 24188 | 20729 | 110544315 |
| Hospitalisation | 116.83 | 23.35 | 150 | 24105 | 142343 | 110422701 |
| Arthralgia | 108.55 | 23.35 | 20 | 24235 | 779612 | 109785432 |
| Abnormal behaviour | 105.21 | 23.35 | 79 | 24176 | 38960 | 110526084 |
| Polydipsia | 101.24 | 23.35 | 44 | 24211 | 7644 | 110557400 |
| Emotional disorder | 96.67 | 23.35 | 54 | 24201 | 16106 | 110548938 |
| Loss of libido | 95.48 | 23.35 | 33 | 24222 | 3100 | 110561944 |
| Sinus tachycardia | 93.98 | 23.35 | 78 | 24177 | 44415 | 110520629 |
| Apraxia | 91.53 | 23.35 | 33 | 24222 | 3507 | 110561537 |
| Hallucination | 91.44 | 23.35 | 112 | 24143 | 101320 | 110463724 |
| Somnolence | 88.55 | 23.35 | 199 | 24056 | 297250 | 110267794 |
| Blood creatine phosphokinase increased | 88.44 | 23.35 | 94 | 24161 | 72983 | 110492061 |
| Rhabdomyolysis | 88.25 | 23.35 | 120 | 24135 | 120281 | 110444763 |
| Personality change due to a general medical condition | 87.80 | 23.35 | 19 | 24236 | 296 | 110564748 |
| Paranoia | 87.75 | 23.35 | 57 | 24198 | 22317 | 110542727 |
| Muscle rigidity | 86.43 | 23.35 | 58 | 24197 | 23973 | 110541071 |
| Sedation complication | 86.36 | 23.35 | 54 | 24201 | 19801 | 110545243 |
| Head titubation | 86.08 | 23.35 | 25 | 24230 | 1332 | 110563712 |
| Pain | 85.51 | 23.35 | 52 | 24203 | 954903 | 109610141 |
| Drug interaction | 82.51 | 23.35 | 269 | 23986 | 499914 | 110065130 |
| Apathy | 80.45 | 23.35 | 48 | 24207 | 16191 | 110548853 |
| Nausea | 80.29 | 23.35 | 92 | 24163 | 1235598 | 109329446 |
| Suicidal ideation | 75.56 | 23.35 | 98 | 24157 | 93839 | 110471205 |
| Drooling | 75.33 | 23.35 | 35 | 24220 | 7104 | 110557940 |
| Sopor | 70.87 | 23.35 | 61 | 24194 | 36485 | 110528559 |
| Headache | 69.73 | 23.35 | 55 | 24200 | 882322 | 109682722 |
| Pruritus | 68.90 | 23.35 | 21 | 24234 | 581539 | 109983505 |
| Sluggishness | 67.35 | 23.35 | 33 | 24222 | 7534 | 110557510 |
| Alopecia | 64.14 | 23.35 | 4 | 24251 | 364749 | 110200295 |
| Peripheral swelling | 63.98 | 23.35 | 7 | 24248 | 404027 | 110161017 |
| Dyspnoea | 63.94 | 23.35 | 90 | 24165 | 1106782 | 109458262 |
| Completed suicide | 63.17 | 23.35 | 154 | 24101 | 242227 | 110322817 |
| Anaemia | 62.59 | 23.35 | 21 | 24234 | 547065 | 110017979 |
| Joint swelling | 62.32 | 23.35 | 11 | 24244 | 442834 | 110122210 |
| Pain in extremity | 56.94 | 23.35 | 18 | 24237 | 487100 | 110077944 |
| Drug abuse | 56.47 | 23.35 | 122 | 24133 | 177289 | 110387755 |
| Rash | 55.53 | 23.35 | 59 | 24196 | 820905 | 109744139 |
| Myelocyte count increased | 54.28 | 23.35 | 16 | 24239 | 898 | 110564146 |
| Overdose | 54.09 | 23.35 | 142 | 24113 | 233652 | 110331392 |
| Oculogyric crisis | 53.97 | 23.35 | 23 | 24232 | 3809 | 110561235 |
| Metamyelocyte count increased | 53.76 | 23.35 | 15 | 24240 | 691 | 110564353 |
| Movement disorder | 53.46 | 23.35 | 52 | 24203 | 36352 | 110528692 |
| Psychiatric symptom | 52.97 | 23.35 | 30 | 24225 | 9183 | 110555861 |
| Pleurothotonus | 52.51 | 23.35 | 20 | 24235 | 2478 | 110562566 |
| Pneumonia | 51.86 | 23.35 | 70 | 24185 | 876644 | 109688400 |
| Infection | 50.94 | 23.35 | 9 | 24246 | 362191 | 110202853 |
| Metabolic syndrome | 50.78 | 23.35 | 21 | 24234 | 3226 | 110561818 |
| Fatigue | 50.51 | 23.35 | 121 | 24134 | 1215837 | 109349207 |
| Condition aggravated | 49.87 | 23.35 | 303 | 23952 | 734533 | 109830511 |
| Drug hypersensitivity | 49.25 | 23.35 | 19 | 24236 | 454071 | 110110973 |
| Nasopharyngitis | 48.97 | 23.35 | 13 | 24242 | 394348 | 110170696 |
| Abnormal weight gain | 48.75 | 23.35 | 21 | 24234 | 3570 | 110561474 |
| Stomatitis | 47.39 | 23.35 | 3 | 24252 | 270239 | 110294805 |
| Febrile neutropenia | 46.49 | 23.35 | 7 | 24248 | 316760 | 110248284 |
| Emotional distress | 46.14 | 23.35 | 53 | 24202 | 44794 | 110520250 |
| Persecutory delusion | 45.94 | 23.35 | 24 | 24231 | 6267 | 110558777 |
| Intentional product misuse | 45.30 | 23.35 | 94 | 24161 | 132810 | 110432234 |
| General physical health deterioration | 44.16 | 23.35 | 19 | 24236 | 425276 | 110139768 |
| Drug resistance | 44.05 | 23.35 | 58 | 24197 | 56316 | 110508728 |
| Blood osmolarity decreased | 42.85 | 23.35 | 15 | 24240 | 1463 | 110563581 |
| Restlessness | 42.61 | 23.35 | 57 | 24198 | 56202 | 110508842 |
| Abdominal pain upper | 42.42 | 23.35 | 12 | 24243 | 349099 | 110215945 |
| Abdominal discomfort | 41.85 | 23.35 | 17 | 24238 | 393841 | 110171203 |
| Electrocardiogram QT prolonged | 41.84 | 23.35 | 81 | 24174 | 108879 | 110456165 |
| Arrhythmia | 41.64 | 23.35 | 63 | 24192 | 69512 | 110495532 |
| Thinking abnormal | 41.59 | 23.35 | 31 | 24224 | 15109 | 110549935 |
| Breast enlargement | 40.89 | 23.35 | 15 | 24240 | 1674 | 110563370 |
| Antipsychotic drug level increased | 40.76 | 23.35 | 23 | 24232 | 6992 | 110558052 |
| Mobility decreased | 40.56 | 23.35 | 3 | 24252 | 237419 | 110327625 |
| Thrombocytopenia | 40.56 | 23.35 | 13 | 24242 | 348872 | 110216172 |
| Swelling | 39.21 | 23.35 | 14 | 24241 | 351027 | 110214017 |
| Wheezing | 38.95 | 23.35 | 5 | 24250 | 255225 | 110309819 |
| Hypersensitivity | 38.94 | 23.35 | 20 | 24235 | 403978 | 110161066 |
| Nephrogenic diabetes insipidus | 38.87 | 23.35 | 16 | 24239 | 2429 | 110562615 |
| Anion gap increased | 38.82 | 23.35 | 19 | 24236 | 4325 | 110560719 |
| Cough | 38.68 | 23.35 | 27 | 24228 | 461614 | 110103430 |
| Schizoaffective disorder | 38.22 | 23.35 | 17 | 24238 | 3119 | 110561925 |
| Wound | 37.25 | 23.35 | 4 | 24251 | 234433 | 110330611 |
| Acute psychosis | 36.34 | 23.35 | 19 | 24236 | 4968 | 110560076 |
| Back pain | 36.30 | 23.35 | 18 | 24237 | 370978 | 110194066 |
| Priapism | 36.19 | 23.35 | 20 | 24235 | 5841 | 110559203 |
| Antipsychotic drug level decreased | 35.90 | 23.35 | 13 | 24242 | 1399 | 110563645 |
| Myoclonus | 35.65 | 23.35 | 40 | 24215 | 32958 | 110532086 |
| Vomiting | 35.12 | 23.35 | 94 | 24161 | 910581 | 109654463 |
| Contusion | 34.60 | 23.35 | 5 | 24250 | 233356 | 110331688 |
| Hypometabolism | 34.06 | 23.35 | 8 | 24247 | 183 | 110564861 |
| Hypertension | 34.05 | 23.35 | 37 | 24218 | 510047 | 110054997 |
| Asthma | 33.53 | 23.35 | 7 | 24248 | 250284 | 110314760 |
| Increased appetite | 33.17 | 23.35 | 27 | 24228 | 14950 | 110550094 |
| Hyponatraemia | 33.06 | 23.35 | 114 | 24141 | 217539 | 110347505 |
| Toxicity to various agents | 33.06 | 23.35 | 199 | 24056 | 480356 | 110084688 |
| Altered state of consciousness | 32.82 | 23.35 | 51 | 24204 | 57575 | 110507469 |
| Hypoaesthesia | 32.67 | 23.35 | 14 | 24241 | 314209 | 110250835 |
| Lower respiratory tract infection | 32.15 | 23.35 | 7 | 24248 | 243099 | 110321945 |
| Erythema | 31.90 | 23.35 | 12 | 24243 | 291435 | 110273609 |
| Psychomotor hyperactivity | 31.73 | 23.35 | 30 | 24225 | 20247 | 110544797 |
| Olfactory nerve disorder | 31.72 | 23.35 | 6 | 24249 | 45 | 110564999 |
| Urinary tract infection | 31.66 | 23.35 | 16 | 24239 | 326266 | 110238778 |
| Decreased appetite | 31.23 | 23.35 | 35 | 24220 | 475811 | 110089233 |
| Drug use disorder | 30.71 | 23.35 | 28 | 24227 | 18046 | 110546998 |
| Troponin increased | 30.32 | 23.35 | 35 | 24220 | 29731 | 110535313 |
| Abdominal pain | 30.23 | 23.35 | 41 | 24214 | 512948 | 110052096 |
| Musculoskeletal pain | 29.39 | 23.35 | 3 | 24252 | 183020 | 110382024 |
| Death | 29.35 | 23.35 | 69 | 24186 | 698800 | 109866244 |
| Lactate pyruvate ratio increased | 29.18 | 23.35 | 6 | 24249 | 72 | 110564972 |
| Monocyte count decreased | 29.00 | 23.35 | 15 | 24240 | 3836 | 110561208 |
| Breast discharge | 28.92 | 23.35 | 10 | 24245 | 940 | 110564104 |
| Diabetes insipidus | 28.90 | 23.35 | 18 | 24237 | 6552 | 110558492 |
| Torticollis | 28.52 | 23.35 | 14 | 24241 | 3207 | 110561837 |
| Hallucination, visual | 28.28 | 23.35 | 39 | 24216 | 39566 | 110525478 |
| Inappropriate antidiuretic hormone secretion | 28.28 | 23.35 | 36 | 24219 | 33815 | 110531229 |
| Regressive behaviour | 27.73 | 23.35 | 7 | 24248 | 218 | 110564826 |
| Housebound | 27.04 | 23.35 | 8 | 24247 | 455 | 110564589 |
| Seizure | 27.02 | 23.35 | 108 | 24147 | 221077 | 110343967 |
| Social avoidant behaviour | 26.93 | 23.35 | 16 | 24239 | 5353 | 110559691 |
| Discomfort | 26.78 | 23.35 | 7 | 24248 | 214700 | 110350344 |
| Inflammation | 26.72 | 23.35 | 5 | 24250 | 193233 | 110371811 |
| Troponin I increased | 26.70 | 23.35 | 16 | 24239 | 5436 | 110559608 |
| Inappropriate affect | 26.61 | 23.35 | 11 | 24244 | 1688 | 110563356 |
| Influenza | 26.57 | 23.35 | 3 | 24252 | 169098 | 110395946 |
| Granulocytopenia | 26.24 | 23.35 | 22 | 24233 | 12693 | 110552351 |
| Psychiatric decompensation | 25.88 | 23.35 | 16 | 24239 | 5749 | 110559295 |
| Blood bicarbonate decreased | 25.80 | 23.35 | 16 | 24239 | 5781 | 110559263 |
| Drug level below therapeutic | 25.76 | 23.35 | 21 | 24234 | 11652 | 110553392 |
| Accidental exposure to product by child | 25.66 | 23.35 | 13 | 24242 | 3185 | 110561859 |
| Maternal exposure during pregnancy | 25.48 | 23.35 | 12 | 24243 | 254871 | 110310173 |
| Irritability | 25.41 | 23.35 | 41 | 24214 | 47768 | 110517276 |
| Drug dependence | 25.37 | 23.35 | 42 | 24213 | 49978 | 110515066 |
| Hepatic enzyme increased | 25.27 | 23.35 | 20 | 24235 | 320872 | 110244172 |
| Sepsis | 25.03 | 23.35 | 21 | 24234 | 327325 | 110237719 |
| Water intoxication | 25.02 | 23.35 | 9 | 24246 | 950 | 110564094 |
| Blood citric acid increased | 24.88 | 23.35 | 5 | 24250 | 53 | 110564991 |
| Behaviour disorder | 24.83 | 23.35 | 19 | 24236 | 9628 | 110555416 |
| Intentional product use issue | 24.28 | 23.35 | 12 | 24243 | 247894 | 110317150 |
| Hyperammonaemic encephalopathy | 24.18 | 23.35 | 15 | 24240 | 5419 | 110559625 |
| Trismus | 23.90 | 23.35 | 16 | 24239 | 6580 | 110558464 |
| Psychomotor retardation | 23.77 | 23.35 | 17 | 24238 | 7775 | 110557269 |
| Asthenia | 23.69 | 23.35 | 75 | 24180 | 688924 | 109876120 |
| Blast cell count increased | 23.63 | 23.35 | 10 | 24245 | 1627 | 110563417 |
| Disease progression | 23.62 | 23.35 | 12 | 24243 | 244022 | 110321022 |
| Rebound psychosis | 23.44 | 23.35 | 7 | 24248 | 411 | 110564633 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AX13 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Other antipsychotics |
| FDA EPC | N0000175430 | Atypical Antipsychotic |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D012702 | Serotonin Antagonists |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D058830 | Serotonin 5-HT2 Receptor Antagonists |
| MeSH PA | D065127 | Dopamine D2 Receptor Antagonists |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35471 | psychotropic drug |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:37890 | α-adrenergic antagonist |
| CHEBI has role | CHEBI:37955 | H<small><sub>1</sub></small>-receptor antagonist |
| CHEBI has role | CHEBI:48279 | serotonergic antagonist |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonist |
| CHEBI has role | CHEBI:49103 | drug metabolite |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:65191 | second generation antipsychotic |
Related Drugs by ATC class:
N05AX Other antipsychotics 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Schizoaffective disorder | indication | 68890003 | DOID:5418 |
| Psychotic disorder | indication | 69322001 | |
| Mixed bipolar I disorder | off-label use | 16506000 | DOID:3312 |
| Bipolar disorder in remission | off-label use | 85248005 | |
| Bipolar affective disorder, current episode manic | off-label use | 191618007 | |
| Bipolar affective disorder, current episode depression | off-label use | 191627008 | DOID:3312 |
| Infantile autism | off-label use | 408857007 | |
| Depression Treatment Adjunct | off-label use | ||
| Priapism | contraindication | 6273006 | DOID:9286 |
| Suicidal thoughts | contraindication | 6471006 | |
| Weight gain finding | contraindication | 8943002 | |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Senile dementia | contraindication | 15662003 | |
| Agranulocytosis | contraindication | 17182001 | DOID:12987 |
| Lowered convulsive threshold | contraindication | 19260006 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Stenosis of intestine | contraindication | 23065003 | |
| Short bowel syndrome | contraindication | 26629001 | DOID:10605 |
| Hypovolemia | contraindication | 28560003 | |
| Orthostatic hypotension | contraindication | 28651003 | |
| Torsades de pointes | contraindication | 31722008 | |
| Parkinsonism | contraindication | 32798002 | |
| Crohn's disease | contraindication | 34000006 | |
| Dehydration | contraindication | 34095006 | |
| Hypokalemia | contraindication | 43339004 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
| Substance abuse | contraindication | 66214007 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Extrapyramidal disease | contraindication | 76349003 | |
| Diffuse Lewy body disease | contraindication | 80098002 | |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Tardive dyskinesia | contraindication | 102449007 | |
| Increased intestinal motility | contraindication | 102624003 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Seizure disorder | contraindication | 128613002 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Angina pectoris | contraindication | 194828000 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
| Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
| Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| At risk for aspiration | contraindication | 371736008 | |
| Impaired cognition | contraindication | 386806002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Gastrointestinal hypomotility | contraindication | 421807004 | |
| Acquired torsion dystonia | contraindication | 433493000 | |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Esophageal Compression | contraindication | ||
| Intestinal Cystic Fibrosis | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.78 | Basic |
| pKa2 | 2.73 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.47 | PDSP | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.96 | PDSP | DRUG LABEL | |||
| Histamine H4 receptor | GPCR | Ki | 5.06 | PDSP | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 7.64 | PDSP | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.89 | CHEMBL | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.43 | PDSP | |||||
| Beta-1 adrenergic receptor | GPCR | Ki | 5.30 | PDSP | |||||
| Beta-2 adrenergic receptor | GPCR | Ki | 5.30 | PDSP | |||||
| D(1A) dopamine receptor | GPCR | Ki | 7.39 | PDSP | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 7.93 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.22 | PDSP | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.21 | PDSP | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.32 | PDSP | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.62 | PDSP | |||||
| Histamine H1 receptor | GPCR | Ki | 8.25 | PDSP | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 8.55 | WOMBAT-PK | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 7.64 | PDSP | |||||
| D(3) dopamine receptor | GPCR | Ki | 9.05 | PDSP | |||||
| D(1B) dopamine receptor | GPCR | Ki | 7.54 | PDSP | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 7.72 | PDSP | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 8.20 | PDSP | |||||
| D(4) dopamine receptor | GPCR | Ki | 7.27 | PDSP | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 9.16 | PDSP | |||||
| 5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.56 | PDSP | |||||
| 5-hydroxytryptamine receptor 1E | GPCR | Ki | 5.99 | PDSP | |||||
| Prostaglandin E2 receptor EP3 subtype | GPCR | Ki | 5 | PDSP | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 8.57 | PDSP | |||||
| Histamine H2 receptor | GPCR | Ki | 6.92 | PDSP |
External reference:
| ID | Source |
|---|---|
| 4025875 | VUID |
| N0000176080 | NUI |
| D05339 | KEGG_DRUG |
| 4025875 | VANDF |
| C0753678 | UMLSCUI |
| CHEBI:82978 | CHEBI |
| CHEMBL1621 | ChEMBL_ID |
| CHEMBL2107360 | ChEMBL_ID |
| D000068882 | MESH_DESCRIPTOR_UI |
| DB01267 | DRUGBANK_ID |
| 7258 | IUPHAR_LIGAND_ID |
| 7977 | INN_ID |
| 838F01T721 | UNII |
| 115237 | PUBCHEM_CID |
| 679314 | RXNORM |
| 23004 | MMSL |
| 92090 | MMSL |
| d06297 | MMSL |
| 011888 | NDDF |
| 425483000 | SNOMEDCT_US |
| 426276000 | SNOMEDCT_US |
| 838F01T721 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6935 | TABLET, FILM COATED, EXTENDED RELEASE | 3 mg | ORAL | ANDA | 31 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6936 | TABLET, FILM COATED, EXTENDED RELEASE | 6 mg | ORAL | ANDA | 31 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6937 | TABLET, FILM COATED, EXTENDED RELEASE | 9 mg | ORAL | ANDA | 31 sections |
| Paliperidone | Human Prescription Drug Label | 1 | 16714-866 | TABLET, FILM COATED, EXTENDED RELEASE | 1.50 mg | ORAL | ANDA | 31 sections |
| Paliperidone | Human Prescription Drug Label | 1 | 16714-867 | TABLET, FILM COATED, EXTENDED RELEASE | 3 mg | ORAL | ANDA | 31 sections |
| Paliperidone | Human Prescription Drug Label | 1 | 16714-868 | TABLET, FILM COATED, EXTENDED RELEASE | 6 mg | ORAL | ANDA | 31 sections |
| Paliperidone | Human Prescription Drug Label | 1 | 16714-869 | TABLET, FILM COATED, EXTENDED RELEASE | 9 mg | ORAL | ANDA | 31 sections |
| INVEGA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-455 | TABLET, EXTENDED RELEASE | 6 mg | ORAL | NDA | 34 sections |
| Paliperidone | Human Prescription Drug Label | 1 | 27241-276 | TABLET, EXTENDED RELEASE | 1.50 mg | ORAL | ANDA | 32 sections |
| Paliperidone | Human Prescription Drug Label | 1 | 27241-277 | TABLET, EXTENDED RELEASE | 3 mg | ORAL | ANDA | 32 sections |
| Paliperidone | Human Prescription Drug Label | 1 | 27241-278 | TABLET, EXTENDED RELEASE | 6 mg | ORAL | ANDA | 32 sections |
| Paliperidone | Human Prescription Drug Label | 1 | 27241-279 | TABLET, EXTENDED RELEASE | 9 mg | ORAL | ANDA | 32 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27808-222 | TABLET, EXTENDED RELEASE | 1.50 mg | ORAL | ANDA | 33 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27808-223 | TABLET, EXTENDED RELEASE | 3 mg | ORAL | ANDA | 33 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27808-224 | TABLET, EXTENDED RELEASE | 6 mg | ORAL | ANDA | 33 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27808-225 | TABLET, EXTENDED RELEASE | 9 mg | ORAL | ANDA | 33 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-317 | TABLET, EXTENDED RELEASE | 1.50 mg | ORAL | ANDA | 20 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-318 | TABLET, EXTENDED RELEASE | 3 mg | ORAL | ANDA | 20 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-319 | TABLET, EXTENDED RELEASE | 6 mg | ORAL | ANDA | 20 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-320 | TABLET, EXTENDED RELEASE | 9 mg | ORAL | ANDA | 20 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-915 | TABLET, EXTENDED RELEASE | 1.50 mg | ORAL | ANDA | 30 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-916 | TABLET, EXTENDED RELEASE | 3 mg | ORAL | ANDA | 30 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-917 | TABLET, EXTENDED RELEASE | 6 mg | ORAL | ANDA | 30 sections |
| Paliperidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-918 | TABLET, EXTENDED RELEASE | 9 mg | ORAL | ANDA | 30 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43602-294 | TABLET, EXTENDED RELEASE | 1.50 mg | ORAL | ANDA | 19 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43602-295 | TABLET, EXTENDED RELEASE | 3 mg | ORAL | ANDA | 19 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43602-296 | TABLET, EXTENDED RELEASE | 6 mg | ORAL | ANDA | 19 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43602-297 | TABLET, EXTENDED RELEASE | 9 mg | ORAL | ANDA | 19 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43975-349 | TABLET, EXTENDED RELEASE | 1.50 mg | ORAL | ANDA | 34 sections |
| PALIPERIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43975-350 | TABLET, EXTENDED RELEASE | 3 mg | ORAL | ANDA | 34 sections |